Neumora Therapeutics stock hits 52-week low at $0.88

Neumora Therapeutics Inc. (NMRA) shares have tumbled to a 52-week low, touching down at $0.88. This significant drop reflects a stark contrast from its previous year’s performance, with the stock experiencing a precipitous 1-year change of -93.59%. According to InvestingPro data, the company’s technical indicators suggest oversold conditions, while maintaining a healthy balance sheet with more cash than debt and a robust current ratio of 10.51. Investors are closely monitoring the biotechnology firm as it navigates through a challenging period marked by this notable decline in its market valuation. The company, which specializes in precision medicines for brain diseases, is now grappling with market dynamics that have pushed its stock to this new low, raising concerns and speculations about its future trajectory among stakeholders. Despite current challenges, three analysts have revised their earnings estimates upward for the upcoming period. For deeper insights into NMRA’s valuation and 15+ additional ProTips, explore the comprehensive research available on InvestingPro.

In other recent news, Neumora Therapeutics has been the focus of several analyst updates following significant developments in its clinical programs. BofA Securities downgraded Neumora from Buy to Underperform, reducing the price target from $7.00 to $1.00. This downgrade follows disappointing results from the phase 3 KOASTAL-1 study, leading to revised trial protocols. Meanwhile, William Blair also downgraded Neumora from Outperform to Market Perform, influenced by Johnson & Johnson’s discontinuation of its aticaprant program, which shares a similar mechanism of action with Neumora’s navacaprant.

Despite these setbacks, H.C. Wainwright maintained a Buy rating for Neumora with an $18.00 price target, emphasizing the potential of navacaprant despite the challenges faced by similar treatments. Stifel, however, lowered its rating from Buy to Hold, with a new price target of $2.00, citing doubts about the efficacy potential of the KORA mechanism following the industry developments. Guggenheim reaffirmed its Buy rating with a $7.00 target, highlighting Neumora’s strategic plans to resume its KOASTAL studies in 2025 and the expected release of topline data in 2026.

The company has paused its KOASTAL-2 and -3 studies and discontinued its Phase II trial in bipolar depression to focus resources on its KOASTAL program. Neumora also plans to advance its next M4 PAM program into clinical trials by mid-2025. These developments come amid leadership changes, with the departure of key executives, as the company navigates the evolving landscape of MDD treatment research.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.